Sulfasalazine and Hair loss for Women aged 30-39 (a phase IV clinical study of FDA data)

Summary:

Hair loss is found for women aged 30-39 who take Sulfasalazine (sulfasalazine). This study is created by eHealthMe based on reports of 3,139 women aged 30-39 from the FDA, and is updated regularly. The information that eHealthMe analyzes includes:

Time on Sulfasalazine when people have Hair loss
Top conditions
Top co-used drugs
Top other side effects

On Aug, 01, 2026

3,139 women aged 30-39 reported to have side effects when taking Sulfasalazine.
Among them, 78 people (2.48%) have Hair loss

What is Sulfasalazine?

Sulfasalazine has active ingredients of sulfasalazine. It is often used in rheumatoid arthritis. eHealthMe is studying from 96,787 Sulfasalazine users. Check the latest studies of Sulfasalazine.

What is Hair loss?

Hair loss is found to be associated with 2,411 drugs and 3,515 conditions by eHealthMe. Check the latest studies of Hair loss.

Number of reports submitted per year:

Could Sulfasalazine cause Hair loss in women aged 30-39?

Time on Sulfasalazine when people have Hair loss *

Severity of Hair loss

n/a

How people recovered from Hair loss

n/a

Top conditions involved for these people *:

You may use this to check any potential undetected conditions.

Type 2 Diabetes: 12 people, 15.38%
Diabetes: 6 people, 7.69%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 6 people, 7.69%
Sinusitis (inflammation of sinus): 5 people, 6.41%
Ankylosing Spondylitis (type of arthritis affecting the spine): 4 people, 5.13%
Pain: 3 people, 3.85%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 3.85%
Postpartum Haemorrhage (bleeding in woman after she has given birth): 1 person, 1.28%
Osteopenia (a condition where bone mineral density is lower than normal): 1 person, 1.28%
Neuroendocrine Tumor: 1 person, 1.28%

Top co-used drugs for these people *:

You may use this to check any potential interacting drugs.

Top other side effects for these people *:

You may use this to check any potential undetected side effects.

Drug Ineffective: 44 people, 56.41%
Abdominal Discomfort: 27 people, 34.62%
Nausea (feeling of having an urge to vomit): 24 people, 30.77%
Mouth Haemorrhage (bleeding from mouth): 21 people, 26.92%
Nosebleed (bleeding from nose): 21 people, 26.92%
Thrombosis (formation of a blood clot inside a blood vessel): 21 people, 26.92%
Headache (pain in head): 21 people, 26.92%
Stress And Anxiety: 19 people, 24.36%
Joint Pain: 19 people, 24.36%
C-Reactive Protein Increased: 19 people, 24.36%

* Approximation only. Some reports may have incomplete information.

Do you take Sulfasalazine and have Hair loss?

- Check whether Hair loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related publications that referenced our studies:

Lindsey SF, Tosti A, "Hair loss induced by tumor necrosis factor alpha inhibitors", J Clin Investigat Dermatol, 2015 Jan .
Lindsey SF, Tosti A, "Hair loss induced by tumor necrosis factor alpha inhibitors", J Clin Investigat Dermatol, 2015 Jan .

Related studies:

Sulfasalazine and Hair loss

How the study uses the data?

The study is based on (applicable) gender, age, sulfasalazine (the active ingredients of Sulfasalazine) and Sulfasalazine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.